Tandem Diabetes Care Stock In The News
| TNDM Stock | USD 19.17 0.99 5.45% |
Our overall analysis of Tandem Diabetes' news coverage and content from conventional and social sources shows investors' bearish mood towards Tandem Diabetes Care. The specific impact of Tandem Diabetes news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Tandem Diabetes' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Tandem Diabetes headlines in addition to utilizing other, more conventional financial analysis modules. Check out Tandem Diabetes Backtesting and Tandem Diabetes Hype Analysis.
Tandem |
Tandem Diabetes Today Top News and Investor Outlook
Tandem Diabetes Care Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Tandem and other traded companies coverage with news coverage. We help investors stay connected with Tandem headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Tandem Stock performance. Please note that trading solely based on the Tandem Diabetes Care hype is not for everyone as timely availability and quick action are needed to avoid losses.
Tandem Diabetes stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Tandem earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Tandem Diabetes that are available to investors today. That information is available publicly through Tandem media outlets and privately through word of mouth or via Tandem internal channels. However, regardless of the origin, that massive amount of Tandem data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tandem Diabetes news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tandem Diabetes relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tandem Diabetes' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tandem Diabetes alpha.
Tandem Largest EPS Surprises
Earnings surprises can significantly impact Tandem Diabetes' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-03 | 2021-09-30 | 0.06 | 0.09 | 0.03 | 50 | ||
2023-11-01 | 2023-09-30 | -0.34 | -0.38 | -0.04 | 11 | ||
2024-11-06 | 2024-09-30 | -0.4 | -0.35 | 0.05 | 12 | ||
2022-02-22 | 2021-12-31 | 0.21 | 0.16 | -0.05 | 23 | ||
2020-11-05 | 2020-09-30 | -0.1 | -0.15 | -0.05 | 50 | ||
2024-08-01 | 2024-06-30 | -0.54 | -0.48 | 0.06 | 11 |
Tandem Diabetes Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Tandem Diabetes Care Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
12th of March 2025
Victory Capital Management Inc. Decreases Stock Position in Tandem Diabetes Care, Inc. - D... at news.google.com
7th of March 2025
Acquisition by Kyrillos Jean-claude of 10538 shares of Tandem Diabetes at 18.1217 subject ... at zdnet.com
5th of March 2025
Tandem Diabetes Care downgraded to Equal-weight on guidance concerns at seekingalpha.com
4th of March 2025
Advisor360 Introduces Tandem A CRM for Independent Financial Advisors at finance.yahoo.com
3rd of March 2025
Tandem Diabetes Care Inc Stock Price Down 2.44 percent on Mar 3 at gurufocus.com
28th of February 2025
Not Many Are Piling Into Tandem Diabetes Care, Inc. Stock Yet As It Plummets 40 at simplywall.st
27th of February 2025
Q4 2024 Tandem Diabetes Care Inc Earnings Call Transcript at gurufocus.com
26th of February 2025
Risen Achieves 30.99 percent Efficiency with HJT-Perovskite Tandem Solar Cells at prnewswire.com
24th of February 2025
Tandem Raises USD 10M in its Pre-seed Round to Revolutionize Pet Healthcare at finance.yahoo.com
13th of February 2025
Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings at globenewswire.com
Tandem Diabetes Investors Sentiment
The influence of Tandem Diabetes' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Tandem. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Tandem Diabetes' public news can be used to forecast risks associated with an investment in Tandem. The trend in average sentiment can be used to explain how an investor holding Tandem can time the market purely based on public headlines and social activities around Tandem Diabetes Care. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Tandem Diabetes' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Tandem Diabetes' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Tandem Diabetes' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Tandem Diabetes.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tandem Diabetes in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tandem Diabetes' short interest history, or implied volatility extrapolated from Tandem Diabetes options trading.
Check out Tandem Diabetes Backtesting and Tandem Diabetes Hype Analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 0.436 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.